ReviewBiomedicines2022
Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Additive efficacy and safety of probiotics in the treatment of ulcerative colitis: a systematic review and meta-analysis.European journal of nutrition · 2024Pooled it
- Protective Effect of a Heat-Stabilized Bacteria Probiotic Preparation (VSL#3-HS) in a Mouse Model of Ulcerative Colitis Induced by Dextran Sulfate Sodium.Molecular nutrition & food research · 2026Article
- Next Generation Probiotics Challenges: A Road to use as Live Bio-Therapeutics.Current microbiology · 2026Review
- Specificity vs. Synergy Between Single-Strain and Multi-Strain Probiotics for Ulcerative Colitis Treatment: A Review of the Literature.Biomedicines · 2026Review
- Gut Microbiome Dysbiosis in Metabolic Syndrome: Current Evidence and Emerging Perspectives.Nutrients · 2026Review
- Restoration of the Mucosal Barrier by Lactobacillus gasseri HDS0266 and Enterococcus faecium HDS0288 in Dextran Sodium Sulfate and Clostridioides difficile-Induced Colitis Mice.Probiotics and antimicrobial proteins · 2026Article
- From One-Size-Fits-All to Precision Medicine: The Promise of Personalized Probiotics.Probiotics and antimicrobial proteins · 2026Review
- Cross-kingdom microbial interactions in the gut during inflammatory bowel disease.Journal of translational medicine · 2026Review
- Probiotics for ulcerative colitis: mechanisms, therapeutic advances, and emerging strategies.Frontiers in microbiology · 2026Review
- Exploring the microbial basis of postbiotic and paraprobiotic therapy in ulcerative colitis.Archives of microbiology · 2025Review
- The impact of Streptococcus thermophilus IDCC 2201 on gut microbiota and its potential as a prophylactic agent for colorectal cancer.Scientific reports · 2025Article
- Evaluation ofFood science & nutrition · 2025Article
- Improvement of the inflammation-damaged intestinal barrier and modulation of the gut microbiota in ulcerative colitis after FMT in the SHIME® model.BMC complementary medicine and therapies · 2025Article
- A Critical Review of Postbiotics as Promising Novel Therapeutic Agents for Clostridial Infections.Probiotics and antimicrobial proteins · 2025Review
- Disclosing the benefits of multi-strain compounds and their health impact mechanisms utilizing intestinal biomimetic technology.Frontiers in microbiology · 2025Article
- Probiotics and human health: biological activities, nutritional aspects, immunomodulatory properties, applications, and future perspectives - a comprehensive review.Frontiers in immunology · 2025Review
- Pre- to Postbiotics: The Beneficial Roles of Pediatric Dysbiosis Associated with Inflammatory Bowel Diseases.Microorganisms · 2024Review
- Interactions between Dietary Antioxidants, Dietary Fiber and the Gut Microbiome: Their Putative Role in Inflammation and Cancer.International journal of molecular sciences · 2024Review
- Pasteurized form of a potential probiotic lactobacillus brevis IBRC-M10790 exerts anti-inflammatory effects on inflammatory bowel disease in vitro.BMC complementary medicine and therapies · 2024Article
- Correction: Štofilová et al. Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches.Biomedicines · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Although there are number of available therapies for ulcerative colitis (UC), many patients are unresponsive to these treatments or experience secondary failure during treatment. Thus, the development of new therapies or alternative strategies with minimal side effects is inevitable. Strategies targeting dysbiosis of gut microbiota have been tested in the management of UC due to the unquestionable role of gut microbiota in the etiology of UC. Advanced molecular analyses of gut microbiomes revealed evident dysbiosis in UC patients, characterized by a reduced biodiversity of commensal microbiota. Administration of conventional probiotic strains is a commonly applied approach in the management of the disease to modify the gut microbiome, improve intestinal barrier integrity and function, and maintain a balanced immune response. However, conventional probiotics do not always provide the expected health benefits to a patient. Their benefits vary significantly, depending on the type and stage of the disease and the strain and dose of the probiotics administered. Their mechanism of action is also strain-dependent. Recently, new candidates for potential next-generation probiotics have been discovered. This could bring to light new approaches in the restoration of microbiome homeostasis and in UC treatment in a targeted manner. The aim of this paper is to provide an updated review on the current options of probiotic-based therapies, highlight the effective conventional probiotic strains, and outline the future possibilities of next-generation probiotic and postbiotic supplementation and fecal microbiota transplantation in the management of UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.